DYN · XBRL financial data
Dyne Therapeutics financial statements, every fiscal year
The same tables from 6 filings, lined up. Matched by XBRL tag: renamed lines keep their history.
How these numbers work
- Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
- Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
- * marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
- 0 means a filing states zero; a dash (—) means no filing states that number.
- “year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
- Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
- Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
- Shares outstanding come from each filing's cover page, as of the date printed there.
- Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.
Income statement
CSVFiscal years (DYN's year ends in late December)
| In millions of dollars | Dec 31, 2020 | Dec 31, 2021 | Dec 31, 2022 | Dec 31, 2023 | Dec 31, 2024 | Dec 31, 2025 |
|---|---|---|---|---|---|---|
| Research and development | 45 | 121 | 143 | 211 | 281 | 398 |
| General and administrative | 13 | 29 | 28 | 31 | 62 | 70 |
| Total operating expenses | 59 | 150 | 171 | 242 | 344 | 468 |
| Other operating income (expense) | — | (0) | (0) | (1) | (0) | (2) |
| Operating income (loss) | (59) | (150) | (171) | (242) | (344) | (468) |
| Other income (expense) | (1) | 1 | 3 | 6 | 26 | 22 |
| Income tax expense (benefit) | — | — | — | 0 | 0 | 0 |
| Net income (loss) | (59) | (149) | (168) | (236) | (317) | (446) |
| Earnings per share, basic USD per share | — | (2.93) | (3.23) | (3.95) | (3.37) | (3.47) |
| Earnings per share, diluted USD per share | — | (2.93) | (3.23) | (3.95) | (3.37) | (3.47) |
Balance sheet
CSVFiscal years (DYN's year ends in late December)
| In millions of dollars | Dec 31, 2020 | Dec 31, 2021 | Dec 31, 2022 | Dec 31, 2023 | Dec 31, 2024 | Dec 31, 2025 |
|---|---|---|---|---|---|---|
| Cash and cash equivalents | 301 | 201 | 172 | 122 | 435 | 893 |
| Marketable securities | 44 | 176 | 84 | 1 | 207 | 217 |
| Prepaid and other current assets | 4 | 6 | 10 | 6 | 17 | 16 |
| Total current assets | 349 | 382 | 266 | 129 | 659 | 1,127 |
| Property and equipment, net | 2 | 5 | 6 | 5 | 5 | 24 |
| Right-of-use asset | 0 | 36 | 32 | 29 | 25 | 21 |
| Total assets | 353 | 426 | 306 | 165 | 691 | 1,187 |
| Accounts payable | 3 | 4 | 5 | 23 | 7 | 8 |
| Total current liabilities | 11 | 29 | 28 | 51 | 42 | 51 |
| Lease liability, non-current | 0 | 29 | 26 | 23 | 19 | 15 |
| Total liabilities | 11 | 57 | 54 | 74 | 61 | 215 |
| Accumulated deficit | (79) | (228) | (397) | (633) | (950) | (1,396) |
| Total stockholders' equity | 342 | 368 | 252 | 91 | 630 | 972 |
| Total liabilities and equity | 353 | 426 | 306 | 165 | 691 | 1,187 |
| Common shares outstanding (cover page) millions of shares | 51 | 52 | 56 | 82 | 113 | 165 |
Cash flows
CSVFiscal years (DYN's year ends in late December)
| In millions of dollars | Dec 31, 2020 | Dec 31, 2021 | Dec 31, 2022 | Dec 31, 2023 | Dec 31, 2024 | Dec 31, 2025 |
|---|---|---|---|---|---|---|
| Net income (loss) | (59) | (149) | (168) | (236) | (317) | (446) |
| Stock-based compensation | 7 | 18 | 15 | 20 | 46 | 46 |
| Depreciation and amortization | 1 | 1 | 2 | 2 | 2 | 2 |
| Net cash from operating activities | (47) | (120) | (154) | (188) | (292) | (403) |
| Purchases of property and equipment | 1 | 4 | 3 | 1 | 2 | 2 |
| Net cash from investing activities | (46) | (138) | 87 | 83 | (204) | (29) |
| Proceeds from issuing common stock | — | — | 37 | 52 | 98 | 141 |
| Proceeds from long-term debt | 10 | — | — | 0 | 0 | 148 |
| Net cash from financing activities | 381 | 158 | 37 | 54 | 810 | 890 |
| Net change in cash | 289 | (100) | (29) | (51) | 313 | 458 |
Compare with peers
SIC 2834 and related industry codes, similar size. Each row is the latest quarter reported.
How peers are chosen
- SIC 2834 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
- Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
- Runway shows only for companies burning cash with under $10B of public float.
- * marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.
- A cell reading “not reported” means the filings give no figure for that quarter alone.
| Company | Cash ($M) | Revenue, quarter ($M) | Operating cash flow, quarter ($M) | Shares outstanding | Runway | Quarter |
|---|---|---|---|---|---|---|
| Dyne Therapeutics | 913 | not reported | (177)* | 187.4M | 6.4 quarters | 10-QSep 30, 2026 |
| Akebia Therapeutics | 156 | 49 | 3.5* | 277.1M | — | 10-QJun 30, 2026 |
| Viridian Therapeutics | 173 | 26 | (93)* | 113.6M | 9.0 quarters | 10-QSep 30, 2026 |
| Collegium Pharmaceutical | 129 | 200 | 71* | 32.6M | — | 10-QJun 30, 2026 |
| Neogen | 172 | 223 | 13 | 218.3M | — | 10-QAug 31, 2026 |
| Ardelyx | 46 | 128 | 2.2* | 251.4M | — | 10-QSep 30, 2026 |
| CorMedix | 257 | 102 | 86* | 77.9M | — | 10-QJun 30, 2026 |
| Aurinia Pharmaceuticals | 46 | 84 | 46* | 134.0M | — | 10-QSep 30, 2026 |
| Harrow | 84 | 71 | (9.8)* | 37.5M | 8.6 quarters | 10-QJun 30, 2026 |
Not investment advice. Not affiliated with the U.S. SEC.